JAK Inhibitors for Hair Restoration
What is JAK Inhibitors for hair loss?
JAK (Janus kinase) inhibitors are prescription medications that suppress specific immune pathways. For hair loss, they are used to treat alopecia areata, an autoimmune condition where the immune system attacks hair follicles causing patchy or total hair loss.
JAK inhibitors treat alopecia areata, not pattern hair loss (androgenetic alopecia). These are different conditions. Alopecia areata is immune-related. Pattern hair loss is caused by genetics and hormones. JAK inhibitors have no established evidence for pattern hair loss.
Two oral JAK inhibitors are FDA-approved for severe alopecia areata: baricitinib (approved 2022) and ritlecitinib (approved 2023).
Does JAK Inhibitors work for hair loss?
Who it applies to
- Adults with moderate-to-severe alopecia areata (immune-related patchy hair loss)
- Prescription only, specialist care required
- Both FDA-approved drugs are for adults with severe alopecia areata
Who it does not apply to
- People with pattern hair loss (androgenetic alopecia)
- People with mild alopecia areata
- Children (baricitinib approved for age 18+; ritlecitinib approved for age 12+)
What to look for when buying
Every spec brands use in marketing — and what the research actually says.
| What brands market | Research verdict | What to look for |
|---|---|---|
| Oral vs topical JAK inhibitors | ✅ Matters | The 2022 review found oral JAK inhibitors significantly outperformed controls. Topical JAK inhibitors showed no significant benefit in the same analysis. |
| Ritlecitinib vs baricitinib | ⚠️ Unclear | No significant difference found in indirect comparison at 24 weeks (2025 NMA). Choice may depend on safety profile, side effects, and individual factors. |
| Recurrence after stopping | ✅ Matters | High recurrence rates were observed after discontinuation in the 2022 review. Ongoing use is typically required to maintain results. |
| For pattern hair loss | ❌ Not researched | No evidence for use in androgenetic alopecia. These drugs target a different mechanism. |
What research cannot tell you
These questions are not answered by any qualified study in our database.
- Which JAK inhibitor is better for your specific case (no direct head-to-head trial)
- Long-term safety beyond studied periods (both drugs are relatively new)
- Whether topical JAK inhibitors will eventually show benefit in larger trials
- Whether JAK inhibitors work for pattern hair loss (not studied)
Research behind this page
All studies are independent systematic reviews or meta-analyses.
| Study | Score | Finding |
|---|---|---|
| JAK inhibitors for alopecia areata — 14 studies | 8/10 | Oral JAK inhibitors significantly outperformed controls; topical showed no benefit; high recurrence after stopping |
| Ritlecitinib vs baricitinib for alopecia areata | 6/10 | No significant difference between ritlecitinib 50mg and baricitinib 4mg at 24 weeks in indirect comparison |
What the research says about common buyer questions
Can JAK inhibitors treat my pattern hair loss?+
No evidence supports this. JAK inhibitors work by suppressing immune pathways that attack hair follicles in alopecia areata. Pattern hair loss has a different cause: genetics and hormone sensitivity, not an immune attack on follicles. These are different conditions requiring different treatments.
What happens when you stop taking them?+
High recurrence rates were observed after stopping in the 2022 review. Unlike some treatments where benefits are maintained after stopping, most alopecia areata patients experience significant hair loss recurrence after discontinuing JAK inhibitor therapy. These are long-term medications requiring specialist monitoring.
Which drug is better, baricitinib or ritlecitinib?+
Current evidence does not confirm one is better than the other. A 2025 network meta-analysis found no significant difference in efficacy between ritlecitinib 50mg and baricitinib 4mg at 24 weeks. The choice is made by a specialist based on individual factors including the patient''s profile and side effect considerations.